MedTrace Logo

Zofin to Treat COVID-19 Long Haulers

NCT05228899 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2023-11-01

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and potential efficacy of Zofin administered intravenously in subjects experiencing prolonged symptoms (\> 6 weeks and \< 24 months) of COVID-19.

Conditions

Interventions

DRUG

Zofin

1mL of Zofin will be administered intravenously, containing 2-5 x 10\^11 particles/mL. Zofin will be diluted in 100 mL of sterile saline.

OTHER

Placebo

1mL of Placebo (normal saline) will be diluted in 100 mL of sterile saline and administered intravenously.

Sponsors & Collaborators

  • ZEO ScientifiX, Inc.

    lead INDUSTRY

Principal Investigators

  • Natasha Phrsai · Proxima

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-14
Primary Completion
2023-10-01
Completion
2023-10-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05228899 on ClinicalTrials.gov